Ikarian Capital LLC Invests $3.09 Million in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Ikarian Capital LLC purchased a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) in the 1st quarter, Holdings Channel.com reports. The firm purchased 105,175 shares of the company’s stock, valued at approximately $3,088,000.

Several other large investors have also modified their holdings of JSPR. Opaleye Management Inc. purchased a new position in Jasper Therapeutics in the fourth quarter worth $3,144,000. Kingdon Capital Management L.L.C. raised its position in Jasper Therapeutics by 16.4% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after acquiring an additional 500,000 shares in the last quarter. Monaco Asset Management SAM purchased a new position in Jasper Therapeutics in the fourth quarter worth $197,000. StemPoint Capital LP purchased a new position in Jasper Therapeutics in the first quarter worth $3,794,000. Finally, Russell Investments Group Ltd. purchased a new position in Jasper Therapeutics in the first quarter worth $2,343,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

NASDAQ:JSPR traded down $1.15 during mid-day trading on Thursday, reaching $17.34. The company’s stock had a trading volume of 152,767 shares, compared to its average volume of 133,030. The company’s fifty day simple moving average is $22.41 and its two-hundred day simple moving average is $21.77. Jasper Therapeutics, Inc. has a twelve month low of $4.00 and a twelve month high of $31.01. The stock has a market cap of $261.14 million, a P/E ratio of -3.18 and a beta of 2.21.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.23. Sell-side analysts expect that Jasper Therapeutics, Inc. will post -4.41 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on JSPR. HC Wainwright reiterated a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research report on Wednesday, May 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a report on Tuesday, June 18th. Evercore ISI initiated coverage on Jasper Therapeutics in a report on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 target price on the stock. Stifel Nicolaus initiated coverage on Jasper Therapeutics in a report on Thursday, June 27th. They issued a “buy” rating and a $86.00 target price on the stock. Finally, BTIG Research initiated coverage on Jasper Therapeutics in a report on Monday, July 8th. They issued a “buy” rating and a $90.00 target price on the stock. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $69.56.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.